Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Research & Development (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Research & Development for 10 consecutive years, with $68.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 13670.8% to $68.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $300.3 million, a 43.39% increase, with the full-year FY2025 number at $300.3 million, up 8.7% from a year prior.
  • Research & Development was $68.9 million for Q4 2025 at Iovance Biotherapeutics, down from $75.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $221.4 million in Q4 2023 to a low of $500000.0 in Q4 2024.
  • A 3-year average of $82.3 million and a median of $78.1 million in 2025 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: plummeted 99.77% in 2024, then surged 13670.8% in 2025.
  • Iovance Biotherapeutics' Research & Development stood at $221.4 million in 2023, then tumbled by 99.77% to $500000.0 in 2024, then soared by 13670.8% to $68.9 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Research & Development are $68.9 million (Q4 2025), $75.2 million (Q3 2025), and $79.4 million (Q2 2025).